Int. Journal of Clinical Pharmacology and Therapeutics, Volume 55 (2017) - February (194 - 200)

The pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects

Sumin Yoon1, SeungHwan Lee1, Kyung-Sang Yu1, Sung-Vin Yim2, Bo-Hyung  Kim2, 3
1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 2 Department of Clinical Pharmacology and Therapeutics, and 3 East-West Medical Research Institute, Kyung Hee University College of Medicine and Hospital, Seoul, Korea

Add to Cart  

 

DOI 10.5414/CP202760

Abstract

Backgrounds: Baclofen is used as a skeletal muscle relaxant for multiple sclerosis patients. It depresses the transmission of monosynaptic and polysynaptic reflex by stimulating GABAβ (gamma-aminobutyric acid) receptors. Objectives: The aim of this study was to compare the pharmacokinetic characteristics of two 10-mg baclofen formulations and to assess bioequivalence. Methods: A randomized, single-dose, two-period, two-sequence crossover study was conducted in healthy male subjects. Each subject received the test or reference formulations. After washout period, all subjects received the alternative formulation. Blood samples were collected for up to 24 hours after the dose in each period. Pharmacokinetic (PK) parameters, including tmax, Cmax, and AUClast were calculated by noncompartmental methods. The geometric mean ratio (GMR) of the test to the reference formulation and its 90% confidence interval (CI) for Cmax and AUClast were calculated for assessment of bioequivalence. Results: A total of 22 subjects completed the study. The median tmax of the test and the reference formulation were 1.50 and 1.25 hours, respectively. The mean (± SD) Cmax of the test and the reference formulation were 141.401 ± 29.447 ng/mL and 138.837 ± 31.392 ng/mL, respectively. The mean (± SD) AUClast of the two formulations were 702.404 ± 82.149 ng×h/mL and 726.803 ± 90.638 ng×h/mL, respectively. The GMR (90% CI) of the test to the reference formulation for the Cmax and AUClast were 1.0306 (0.9564 – 1.1106) and 0.9674 (0.9437 – 0.9916), respectively. Conclusions: The two different baclofen 10-mg formulations had similar PK profiles and were bioequivalent based on Cmax and AUClast.


Author Details

Authors

Departments

  • 1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital,
  • 2 Department of Clinical Pharmacology and Therapeutics, and
  • 3 East-West Medical Research Institute, Kyung Hee University College of Medicine and Hospital, Seoul, Korea

Address

Bo-Hyung Kim, MD, PhD
Department of Clinical Pharmacology and Therapeutics
Kyung Hee University College of Medicine and Hospital
23 Kyungheedae-ro, Dongdaemun-gu,
Seoul 02447, Korea
Email: [email protected]

Log in for Subscribers

Citation

Sumin Yoon, SeungHwan Lee, Kyung-Sang Yu, Sung-Vin Yim, Bo-Hyung  Kim.The pharmacokinetic comparison and bioequivalence evaluation of two 10-mg baclofen formulations in healthy male subjects
. 2017; 55: 194-200. doi: 10.5414/CP202760.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart